Article

Incidence of atrial fibrillation post-cavotricuspid isthmus ablation in patients with typical atrial flutter: Left-atrial size as an independent predictor of atrial fibrillation recurrence

Center for Atrial Fibrillation, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA.
Journal of Cardiovascular Electrophysiology (Impact Factor: 3.48). 09/2007; 18(8):799-802. DOI: 10.1111/j.1540-8167.2007.00885.x
Source: PubMed

ABSTRACT Atrial fibrillation and atrial flutter often coexist. The long-term occurrence of atrial fibrillation in patients presenting with atrial flutter alone is unknown. We report the long-term follow-up in patients who underwent cavotricuspid isthmus ablation for treatment of lone atrial flutter.
Between January 1997 and June 2002, 632 patients underwent cavotricuspid isthmus ablation for the treatment of typical atrial flutter at the Cleveland Clinic Foundation. Three hundred sixty-three patients were included in this study and followed for a mean duration of 39 +/- 11 months. The mean duration of atrial flutter symptoms was 12 +/- 5 months. Mean left-atrial size and left-ventricular ejection fraction were 4.2 +/- 0.8 cm and 47 +/- 13%, respectively. After a mean follow-up time of 39 +/- 11 months, 13% (48 of 363) of the patients remained in sinus rhythm. Five percent (18 of 363) of patients experienced recurrence of atrial flutter only. Sixty-eight percent (246 of 363) experienced the onset of atrial fibrillation and 14% (51 of 363) experienced recurrence of atrial flutter and the new onset of atrial fibrillation. Overall, 82% (297 of 363) of the patients experienced new onset of drug refractory atrial fibrillation. Left-atrial size was a predictor of atrial fibrillation recurrence post-atrial flutter ablation.
At long-term follow-up, approximately 82% of patients post-cavotricuspid isthmus ablation for atrial flutter developed drug refractory atrial fibrillation. This finding suggests that elimination of atrial flutter might delay, but does not prevent, atrial fibrillation. Evidence suggests both arrhythmias may share common triggers and such patients may derive a better long-term benefit from anatomical ablative treatment of atrial fibrillation as well.

1 Bookmark
 · 
92 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND Radiofrequency ablation (RFA) is considered a curative procedure for typical atrial flutter (AFL); however, patients remain at risk for developing new atrial fibrillation (AF). OBJECTIVE The purpose of this study was to determine the incidence and predictors of new-onset AF and stroke after RFA of isolated AFL in a multicenter cohort. METHODS The study included 315 consecutive patients who underwent successful RFA of isolated, typical AFL from 2006 to 2013 at 4 community and teaching hospitals. Patients with any history of AF prior to RFA were excluded. RESULTS During 2.5 +/- 7 1.8 years of follow-up after RFA, 80 patients (25%) developed new AF. In multivariate analysis, after adjusting for baseline medical therapy, obstructive sleep apnea and Left atrial enlargement were independently associated with the development of new AF. Presence of a cardiac implantable electronic device (CIED) was associated with a 3.6-fold (95% confidence interval 1.9-6.6, P <.0001) increase in the likelihood of AF detection. New AF was detected in 48% of patients with CIED and 35% of those who underwent Hotter ECG vs 190/0 of those with clinical follow-up only (P <.0001). Anticoagulation was stopped in 58% patients an average of 3.3 +/- 4.8 months after RFA. Stroke occurred in 3 patients (1%) during the follow-up period. CONCLUSION New AF occurs in >25% of patients after RFA of isolated typical AFL, but stroke is relatively rare. Obstructive sleep apnea and left atrial enlargement are risk factors for AF. The presence of a CIED significantly enhances the likelihood of detecting new AF, demonstrating the importance of arrhythmia surveillance after RFA of AFL.
    Heart rhythm: the official journal of the Heart Rhythm Society 07/2014; 11(11). DOI:10.1016/j.hrthm.2014.06.038 · 4.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The relationship between atrial fibrillation (AF) and cavotricuspid isthmus (CTI) -dependent atrial flutter (AFL) has long been recognized in clinical practice. The development of both is favored by the presence of common triggers and substrate, particularly in the setting of structural heart disease with its attendant electrical and structural remodelling. Conditions associated with atrial remodelling including heart failure, hypertension, increasing age and valvular heart disease predispose to both fibrillation and flutter.This article is protected by copyright. All rights reserved.
    Journal of Cardiovascular Electrophysiology 04/2014; 25(8). DOI:10.1111/jce.12446 · 3.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although catheter ablation of isthmus-dependent atrial flutter (AFL) is successful at eliminating the target arrhythmia, many patients subsequently experience new onset atrial fibrillation (AF). To determine if AF can be prevented by prophylactic pulmonary vein ablation in patients with AFL. A prospective single-blind randomized clinical trial in patients whose sole arrhythmia was AFL without AF was conducted. Patients were randomized to cavo-tricuspid isthmus ablation alone or with concomitant pulmonary vein isolation. All patients received an implantable cardiac monitor. 50 patients completed the trial and patients were well-matched. Isthmus ablation was successful in all patients; pulmonary vein isolation was successful in the 25 randomized patients. Procedure (p < 0.0001) and fluoroscopy (p < 0.0001) times were longer in the combined ablation group. More patients in the isthmus ablation only group experienced new onset AF, 52% vs 12%, during follow-up (p = 0.003). The one-year AF burden also favored the combined ablation group compared to the isthmus ablation only group: 8.3% vs 4.0% (p = 0.034). In the isthmus ablation only group, 32% patients subsequently underwent another ablation for AF. The performance of pulmonary vein isolation and male gender were independent predictors of freedom from AF. In the PREVENT-AF Study I randomized clinical trial of patients in whom only typical AFL had been observed clinically, the addition of pulmonary vein isolation to cavo-tricuspid isthmus ablation resulted in a marked reduction of new onset AF during clinical follow-up as assessed by continuous implantable cardiac monitor.
    Heart rhythm: the official journal of the Heart Rhythm Society 05/2014; 11(9). DOI:10.1016/j.hrthm.2014.05.011 · 4.56 Impact Factor